Similar Posts
New Marketing Authorization Approval in Cambodia for new indication of locally advanced unresectable or metastatic pancreatic cancer.
ByInnokeys
On 24 Sep 2019, Cambodia Ministry of Health approved new marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer for…
Webinar – The Role of Nimotuzumab in the Treatment of Head and Neck and Nasopharyngeal Cancer
ByInnokeys
This webinar was conducted on May 28th, 2022 discussing the role of Nimotuzumab in the treatment of locally advanced squamous cell…
Webinar – How to Treat Locoregional Reccurent Disease of Nasopharyngeal Cancer
ByInnokeys
Speakers: 1. dr. Raymond King-Yin TSANG, MBChB, MS, FRCSEd, FRCSEd(ORL), FHKCORL, FHKAM(Otorhinolaryngology) as Head of the Division of Otorhinolaryngology of the…
ASCO 2013 : Nimotuzumab Abstracts
ByInnokeys
Professor Dirk Strumberg from Germany (center, in blue suit), the principal investigator of phase IIB/IIIA nimotuzumab clinical trial on pancreatic cancer, in…
August 2013: Nimotuzumab in MOGA Australia
ByInnokeys
Medical Oncology Group of Australia
Patent Pending for “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” in numerous countries
ByInnokeys
Application for patents with the title of “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” are…